Whether or not these CD8+ T cell targeted treatments will ultimately be beneficial for both JSLE and associated atherosclerosis will likely depend on the specific cell subsets, tissue penetration and JSLE phenotype specificity, disease activity and stage of atherosclerotic lesion progression. The gene discussed is CD8A; the disease is atherosclerosis.